Investing in Qura: the case for a new health paradigm
March 3rd, 2026
We treat health like an emergency instead of a priority. Qura changes that.
When something is acutely wrong — a broken bone, a cardiac event, a sudden infection — the system responds. But for the vast majority of people, navigating health looks very different. It looks like months of fatigue that no GP takes seriously. It looks like hormonal imbalances dismissed as stress. It looks like a digestive problem that bounces between three specialists without resolution. It looks like being handed a lab report with no context, and turning to Google for answers.
This is not a niche problem. An estimated one in five adults in Europe lives with persistent subclinical symptoms — conditions that fall below the threshold of a formal diagnosis, but substantially erode quality of life. The system has no mechanism to address them proactively. Consultations are too short. Diagnostics are siloed. No one is connecting the dots.
The result is a structural gap that is large, growing, and largely unaddressed. The European health check-up market is projected to reach €18.6 billion by 2030. EU countries spent €90.4 billion on preventive care in 2022 alone. The demand is there. What has been missing is the infrastructure to serve it intelligently.
That is what Qura is building.
A new paradigm, not a new app
The digital health space is crowded with point solutions — symptom trackers, supplement subscriptions, telemedicine platforms, wearable dashboards. Most of them generate data. Very few generate clarity. And almost none of them close the loop between data, clinical interpretation, and a concrete plan of action.
Qura is designed differently. Members begin with comprehensive blood testing at one of Qura’s partner laboratories. Results are processed through a proprietary AI health-mapping engine that connects biomarker data with symptoms and lifestyle patterns. Every analysis is reviewed by a licensed physician. This is followed by a 45-minute personalised consultation, where the medical team walks the user through their health map and delivers a tailored intervention protocol — covering nutrition, supplementation, sleep, stress regulation, and behavioural adjustments. Periodically, users retest. The AI updates their health map based on biomarker evolution. The loop closes.
This is not a chatbot and it is not a wellness app. It is a fully integrated, longitudinal health system — one that treats the patient as a whole, tracks them over time, and gets smarter with every interaction.
The model’s defining architectural choice is the hybrid human-AI approach. Doctors remain at the centre of the experience. AI enhances their efficiency, sharpens personalisation, and builds the longitudinal data layer that makes recommendations increasingly precise. This is not AI replacing clinical judgment — it is AI making clinical judgment scalable. That distinction matters enormously, both for regulatory alignment and for consumer trust.
Why the moat is real
We look for businesses where the structural advantages compound over time. Qura has three that matter.
The first is the learning engine. Every test processed, every consultation completed, every protocol delivered feeds back into the model. The system becomes more accurate, more personalised, and more defensible with scale. This is a compounding advantage that lightweight competitors — consumer apps, static lab services — cannot replicate without the same longitudinal data.
The second is regulatory depth. Qura is building EU-native infrastructure from the ground up: GDPR-compliant, medically validated, integrated with local laboratory networks. Regulatory alignment in European healthcare is genuinely hard. It is also genuinely valuable. It opens distribution channels — employers, insurers, national health systems — that are closed to players who treat compliance as an afterthought. And it raises a barrier that fast-moving replicas will struggle to cross.
The third is the institutional opportunity. Insurers across Europe face rising avoidable costs: repeated specialist visits, duplicated diagnostics, unmanaged chronic conditions, claims that could have been prevented with earlier intervention. Qura’s longitudinal health data is precisely the asset insurers need to identify risk early, personalise products, and reduce preventable claims. Qura as infrastructure for insurers and employers is the long-term platform play.
The team
Thesis alone does not justify conviction. The founding team does.
Virginia Gambardella did not arrive at this problem theoretically. She bootstrapped Italy’s first mindfulness app to €30,000 in monthly recurring revenue, built a health-focused community of over 500,000 people, and served as Head of Operations at Serenis, one of Italy’s leading digital therapy platforms — after starting her career at McKinsey. She understands how to grow a consumer health product, how to operate at scale, and how to build trust with an audience that is deeply sceptical of health technology that overpromises.
CTO and co-founder Gioacchino Grand is a two-time founding engineer who has scaled technology teams from pre-seed to Series A. He brings the infrastructure depth that a platform of this ambition requires.
Together, they have built early traction that validates the core hypothesis: people are willing to pay, repeatedly, for a health experience that actually gives them answers.
The ambition
By 2030, Qura aims to become the missing middle layer of modern European healthcare — the system that sits between the individual and the traditional care infrastructure, connecting fragmented data into a coherent health picture, and translating that picture into action.
The vision extends beyond consumers. A future where Qura’s health intelligence layer integrates with how insurers price risk, how employers structure benefits, and how care providers design preventive pathways is a large and plausible one. The infrastructure being built today — the lab integrations, the clinical validation, the AI engine, the regulatory framework — is the foundation for that platform.
We are proud to lead this round, and to back a team that is building with the rigour and ambition the opportunity deserves.
United Ventures led Qura’s €1.5M pre-seed round. The round also includes participation from Vento and Italian Angels for Growth.
